Posted by Michael Wonder on 08 Jan 2024
FDA grants Soligenix fast track designation for dusquetide in the treatment of oral lesions of Behçet's disease
8 January 2024 - Soligenix announced today that its SGX945 (dusquetide) development program for the treatment of oral lesions of Behçet's disease has received "Fast Track" designation from the US FDA.
Dusquetide (the active ingredient in SGX945 (Behçet's disease) and SGX942 (oral mucositis)) is an innate defense regulator, a new class of short, synthetic peptides.
